Applications of Yttrium-90 (90Y) in Hepatocellular Carcinoma
ZhongHao Jiang,Fan Yang,WanXiang Wang
DOI: https://doi.org/10.2147/ott.s445898
IF: 4
2024-02-23
OncoTargets and Therapy
Abstract:ZhongHao Jiang, Fan Yang, WanXiang Wang Inner Mongolia Medical University, Department of Hepatobiliary Surgery, Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, 010050, People's Republic of China Correspondence: WanXiang Wang, Inner Mongolia Medical University, Department of Hepatobiliary Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot North Street, Inner Mongolia, 010050, People's Republic of China, Email Hepatocellular carcinoma (HCC) is the most common primary liver cancer, affecting millions of people worldwide. Due to the lack of systemic radiation therapy in hepatocellular carcinoma, researchers have been investigating the use of yttrium-90 ( 90 Y) radioembolization for local-regional tumor control since the 1960s. With the development of glass and resin 90 Y microspheres and the durable local control, good long-term efficacy, and equivalent tumor responsiveness and tolerability of 90 Y-selective internal irradiation compared with alternative therapies such as transarterial chemoembolization (TACE) and sorafenib, 90 Y radioembolization has gradually been applied in the treatment of hepatocellular carcinoma of all stages. In this article, we summarize the latest progress of 90 Y in the treatment of hepatocellular carcinoma in terms of its principle, advantages, indications, contraindications, efficacy and adverse effects. Keywords: yttrium-90, hepatocellular carcinoma, internal radioembolisation Liver cancer, ranking as the sixth most prevalent malignant tumor globally, poses a significant global health challenge due to its high mortality rate. The World Health Organization projects that over one million individuals will succumb to liver cancer by 2030 based on current projections. 1 Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for 75% to 80% of all liver cancers. Its onset is often linked to various liver diseases such as viral hepatitis, alcoholic fatty liver, and non-alcoholic fatty liver. 2 Primary treatment modalities for liver cancer include traditional surgical resection, percutaneous anhydrous ethanol injection, transarterial chemoembolization (TACE), ablation therapy, liver transplantation, and chemotherapy, among others. Surgical intervention is effective for early-stage liver cancer, achieving complete cure. However, a significant proportion of liver cancer patients, around 70%, are diagnosed at an intermediate or advanced stage, thereby missing the window for surgical intervention. 3 Liver transplantation (LT) is the most effective treatment for liver cancer. Unfortunately, a substantial number of patients do not meet the Milan criteria, rendering them ineligible for transplantation. Radiotherapy, aimed at downsizing the tumor, plays a crucial role in enabling subsequent liver resection or transplantation. The advent of novel technologies and materials has given rise to 90 Y selective internal irradiation as a new approach for treating advanced hepatocellular carcinoma, and this article provides an overview of recent advancements in this technique. Studies have demonstrated the radiosensitivity of hepatocellular carcinoma cell lines in vitro. 4 However, due to the radiosensitivity of normal liver tissue, exposing the entire liver to an average radiation dose exceeding 43 Gy results in liver dysfunction in more than 50% of patients. 5 Consequently, the utilization of external radiation therapy has historically been limited, with conventional fractionated therapy restricted to doses below 40 Gy for most normal livers, proving ineffective for treating hepatic malignancies. 6 T This limitation stems from the potential occurrence of Radiation-induced Liver Damage (RILD) due to irradiation of a significant portion of the normal liver. The concept of intrahepatic transcatheter arterial-directed therapy originated from groundbreaking research by pathologists at the University of Pennsylvania. They demonstrated that the portal vein is the primary source of blood to the normal hepatic parenchyma, while hepatic tumors, highly vascular structures, are predominantly supplied by the hepatic artery and its branches. Notably, hepatic tumors lack the dual parenchymal blood supply provided by both hepatic arteries and the portal vein. 7,8 Additionally, the blood supply to these tumors may also be parasitic from extrahepatic sites. The celiac trunk branches into the common hepatic artery, which further divides into the right and left lobar hepatic arteries, supplying blood to the respective liver lobes. This unique anatomical structure allows for the transarterial delivery of therapeutic substances like radioactive microspheres. 9,10 Consequently, transarterial internal radiat -Abstract Truncated-
oncology,biotechnology & applied microbiology